Maze Therapeutics (NASDAQ:MAZE) CMO Sells 5,189 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 5,189 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $134,965.89. Following the sale, the chief marketing officer owned 9,705 shares of the company’s stock, valued at $252,427.05. This trade represents a 34.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total transaction of $135,155.82.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total transaction of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Stock Performance

Shares of NASDAQ:MAZE traded up $0.34 during mid-day trading on Friday, reaching $26.21. The company had a trading volume of 273,266 shares, compared to its average volume of 637,671. Maze Therapeutics, Inc. has a one year low of $14.27 and a one year high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average price is $28.74 and its 200-day moving average price is $31.20. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). As a group, equities research analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. BTIG Research reiterated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Maze Therapeutics presently has an average rating of “Buy” and a consensus target price of $66.00.

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada lifted its position in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Maze Therapeutics in the fourth quarter valued at $43,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Maze Therapeutics during the 2nd quarter valued at $48,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.